COMPOSITIONS AND METHODS FOR TREATING CANCER

• US 20190307787A1
• Filed: 04/09/2019
• Published: 10/10/2019
• Est. Priority Date: 04/10/2018
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Chinnaiyan, Arul, Malik, Rohit, Zhang, Yajia, Cieslik, Marcin, Pitchiaya, Sethuramasundaram
• Granted Patent: US 11,013,754 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/113 targeting other non-coding nucleic acids, e.g. antagomirs
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/141 MicroRNAs, miRNAs
• CPC Class Codes: C12N 2310/531 Stem-loop; Hairpin
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.

Claims

1. A method of treating cancer, comprising:

administering an agent that blocks the expression or activity of ARlnc1 to a subject diagnosed with cancer under conditions such that a sign or symptom of said cancer is reduced.

2. The method of claim 1, wherein said agent is a nucleic acid that inhibits expression of ARlnc1.

3. The method of claim 1, wherein said nucleic acid is selected from the group consisting of a siRNA, a shRNA, a miRNA, and an antisense oligonucleotide.

4. The method of claim 1, wherein said cancer is prostate cancer.

5. The method of claim 1, wherein said cancer expresses ARlnc1.

6. The method of claim 5, wherein ARlnc1 is overexpressed in said cancer relative to the level of expression in non-cancerous cells.

7. The method of claim 1, wherein said method further comprises the step of assaying a sample of said cancer for the level of expression of ARlnc1.

8. A method, comprising:

a) assaying a sample from a subject diagnosed with cancer, wherein said sample comprises cancer tissue or cells for the level of expression of ARlnc1; and

b) administering an agent that blocks the expression or activity of ARlnc1 when expression of ARlnc1 is present in said sample.

9. The method of claim 8, wherein said agent is a nucleic acid that inhibits expression of ARlnc1.

10. The method of claim 8, wherein said nucleic acid is selected from the group consisting of a siRNA, a shRNA, a miRNA, and an antisense oligonucleotide.

11. The method of claim 8, wherein said cancer is prostate cancer.

12. A composition, comprising:

a) an agent that inhibits expression of ARlnc1; and

b) a pharmaceutically acceptable carrier.